Relationship between high density lipoprotein antioxidant activity and carotid arterial intima-media thickness in patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 32, Issue 1, 2010, Pages 13-20

  Chen, Xiaoping ^a   Wu, Yuelei ^a   Liu, Liyun ^a   Su, Yanling ^a   Peng, Yong ^a   Jiang, Lingyun ^a   Liu, Xiaojing ^a   Huang, Dejia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antioxidative activity; Carotid arterial intima media thickness (CIMT); High density lipoprotein (HDL); Hypertension; Paraoxonase 1 (PON1) activity

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHENYLACETIC ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY GRADIENT CENTRIFUGATION; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; MONITORING; OXIDATION; REGRESSION ANALYSIS; SPECTROPHOTOMETRY; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CAROTID ARTERIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; TUNICA INTIMA; TUNICA MEDIA;

EID: 77149136764     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641960902929487     Document Type: Article

References (22)

1. von Eckardstein A, Nofer JR, Assmann G. Acceleration of reverse cholesterol transport. Current Opinion in Cardiology 2000;15:348-354.
2. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-2756.
3. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis 2002; 161:1-16.
4. Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004;109:IV22-30.
5. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004;109:III33-38.
6. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-135.
7. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidative capacity. Free Radical Research 2003; 37(1):77-83.
8. Yang YH, Xia Y, Yuan SH, He L. Relationship between activity of PON21 and coronary artery disease. Clinical Focus 2005;20:1-3.
9. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Castaldo M, Fontana L, et al. The paraoxonase promoter polymorphism (-107)T > C is not associated with carotid intimamedia thickness in Sicilian hypercholesterolemic patients. Clinical Biochemistry 2004;37(5): 388-394.
10. Cao HB, Girard-Globa A, Serusclat A, Bernard S, Bondon P, Picard S, et al. Lack of association between carotid intimamedia thickness and paraoxonase gene polymorphism in noninsulin dependent diabetes mellitus. Atherosclerosis 1998;138(2):361-366.
11. Harangi M, Seres I, Magyar MT, Csipo I, Sipka S, Valikovics A, et al. Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease. Cerebrovasc Dis 2008;25:122-128.
12. Zhang LH, Liu BW. Separation of human serum lipoproteins by one-step density gradient ultracentrifugation. Acta Biochimica et Biophysica Sinica 1989;21:257-260.
13. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75.
14. Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio F, Wikinski R, et al. Impaired high density lipoprotein antioxidative activity in healthy postmenopausal women. Atherosclerosis 2004;177:203-210.
15. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
16. Kastelein JJP, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine 2007;356: 1620-1630.
17. Steven EN, Jean CT, Stephen JN, Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. New England Journal of Medicine 2007;356:1304-1316.
18. Bots ML,Visseren FL, Evans GW, Riley WA, Shear CL, Duggan WT, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. New England Journal of Medicine 2007;370:153-160.
19. Jurek A, Turyna B, Kubit P, Klein A. LDL susceptibility to oxidation and HDL antioxidative capacity in patients with renal failure. Clin Biochem 2006;39:19-27.
20. Sanguinetti SM, Brites FD, Fasulo V, Verona J, Elbert A, Wikinski R L, et al. HDL oxidability and its protective effect against LDL oxidation in type 2 diabetic patients. Diabetes Nutr Metab 2001;14:27-36.
21. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004;15:399-404.
22. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-541.